Sanofi S.A. operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Sanofi S.A. with three other companies in this sector in UNITED STATES : Bristol-Myers Squibb Company (2020 sales of $42.52 billion of which 28% was Prioritized Brands-Revlimid), Pfizer Inc. ($41.91 billion of which 26% was Oncology), and GlaxoSmithKline plc ($44.07 billion of which 50% was Pharmaceuticals).

Sales Analysis. During the year ended December of 2020, sales at Sanofi S.A. were $42.87 billion. This is a very small increase of 1.9% versus 2019, when the company's sales were $42.06 billion. This was the fourth straight year of sales growth at Sanofi S.A.. Sales of Vaccines saw an increase that was more than double the company's growth rate: sales were up 7.0% in 2020, from $6.41 billion to $6.85 billion. Sanofi S.A. also saw significant increases in sales in Pharmaceuticals (up 2.5% to $29.45 billion) . Not all segments of Sanofi S.A. experienced an increase in sales in 2020: sales of Consumer Healthcare fell 3.8% to $5.04 billion.